Chris Tame

Chief Executive Officer Ternary Therapeutics

Chris has over 18 years experience in drug discovery, working across all preclinical phases, from Target ID to Candidate Selection. Chris started his career in 2007 as a medicinal chemist at  GSK and was part of the group that pioneered PROTACs through a collaboration with Craig Crews and Alessio Ciulli. In 2017 he moved to BenevolentAI and led techbio teams in target ID and early discovery chemistry, including the BAI-AZ collaboration in IPF. In 2024 he founded Ternary Therapeutics, a techbio company with a novel computational platform for the design of molecular glues. Ternary is based in London, UK.

Seminars

Thursday 29th January 2026
Accurate Prediction of Tractable Ternary Complexes & Optimised Molecular Glues for Any Protein-Protein Interaction
12:30 pm
  • An overview of Ternary’s end-to-end molecular glue design platform
  • Revealing in vitro validation of the platform
  • Exploring current limitations to AI-enabled molecular glue design
Headshot - Chris Tame